GURUFOCUS.COM » STOCK LIST » Europe » Germany » FRA » IVERIC bio Inc (FRA:O2T) » Definitions » Construction In Progress
Switch to:

IVERIC bio (FRA:O2T) Construction In Progress

: €0.00 Mil (As of Dec. 2022)
View and export this data going back to 2013. Start your Free Trial

IVERIC bio Construction In Progress Historical Data

The historical data trend for IVERIC bio's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVERIC bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Construction In Progress
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

IVERIC bio Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Construction In Progress Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

IVERIC bio Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


IVERIC bio (FRA:O2T) Business Description

IVERIC bio logo
Traded in Other Exchanges
Address
8 Sylvan Way, Parsippany, New Jersey, USA, 07054
IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.

IVERIC bio (FRA:O2T) Headlines

No Headlines